


Pioglitazone cuts diabetes risk after ischemic stroke, TIA

August 5 2016



(HealthDay)—For insulin-resistant patients with recent ischemic stroke

or transient ischemic attack, pioglitazone is associated with reduced risk of diabetes, according to a study published online July 27 in *Diabetes Care*.

Silvio E. Inzucchi, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues examined the metabolic effects of pioglitazone and [diabetes prevention](#) in a trial involving 3,876 patients with recent ischemic stroke or [transient ischemic attack](#), no history of diabetes, fasting plasma glucose (FPG) 3.0. Participants were randomized to receive pioglitazone or placebo.

The researchers found that the mean HOMA-IR and FPG decreased in the pioglitazone group and increased in the placebo group (all P

"Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Takeda Pharmaceuticals, which provided [pioglitazone](#) and placebo.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Pioglitazone cuts diabetes risk after ischemic stroke, TIA (2016, August 5) retrieved 24 April 2024 from <https://medicalxpress.com/news/2016-08-pioglitazone-diabetes-ischemic-tia.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.